Metropolitan Heart and Vascular Institute, Mercy Hospital, Minneapolis, Minnesota, USA.
Clinical & Medical Affairs, Cardiovascular Systems Inc., St. Paul, Minnesota, USA.
Catheter Cardiovasc Interv. 2022 Oct;100(4):553-559. doi: 10.1002/ccd.30369. Epub 2022 Aug 21.
To evaluate the feasibility and safety of coronary orbital atherectomy (OA) for the treatment of calcified ostial lesions.
Percutaneous coronary intervention (PCI) is increasingly being completed in complex patients and lesions. OA is effective for severely calcified coronary lesions; however, there is a dearth of evidence on the use of OA in ostial lesions, especially with long-term outcome data.
Data were obtained from a retrospective analysis of patients who underwent OA of heavily calcified ostial lesions followed by stent implantation from December 2010 to June 2019 at two high-volume PCI centers. Kaplan-Meier analysis was utilized to assess the primary endpoints of 30-day, 1-year, and 2-year freedom-from (FF) major adverse cardiac events (MACE: death, myocardial infarction, or target vessel revascularization), stroke, and stent thrombosis (ST).
A total of 56 patients underwent OA to treat heavily calcified ostial coronary lesions. The mean age was 72 years with a high prevalence of diabetes (55%) and heart failure (36%), requiring hemodynamic support (14%). There was high FF angiographic complications (93%), and at 30-day, 1-year, and 2-year, a high FF-MACE (96%, 91%, and 88%), stroke (98%, 96%, and 96%), and ST (100%), respectively.
This study represents the largest real-world experience of coronary OA use in heavily calcified ostial lesions with long-term outcomes over 2 years. The main finding in this retrospective analysis is that, despite the complex patients and lesions included in this analysis, OA appears to be a feasible and safe treatment option for calcified coronary ostial lesions.
评估冠状动脉轨道旋磨术(OA)治疗钙化开口病变的可行性和安全性。
经皮冠状动脉介入治疗(PCI)越来越多地应用于复杂患者和病变。OA 对严重钙化的冠状动脉病变有效;然而,关于 OA 在开口病变中的应用,特别是长期结果数据,证据不足。
从 2010 年 12 月至 2019 年 6 月在两个高容量 PCI 中心接受重度钙化开口病变的 OA 联合支架植入术的患者中进行回顾性分析,获取数据。采用 Kaplan-Meier 分析评估 30 天、1 年和 2 年免于(FF)主要不良心脏事件(MACE:死亡、心肌梗死或靶血管血运重建)、卒中和支架血栓形成(ST)的主要终点。
共有 56 例患者接受 OA 治疗重度钙化开口冠状动脉病变。平均年龄为 72 岁,糖尿病(55%)和心力衰竭(36%)患病率高,需要血流动力学支持(14%)。FF 血管造影并发症发生率高(93%),30 天、1 年和 2 年的 FF-MACE(96%、91%和 88%)、卒中和 ST(98%、96%和 96%)发生率高。
这项研究代表了最大的真实世界经验,涉及冠状动脉 OA 在重度钙化开口病变中的应用以及 2 年以上的长期结果。回顾性分析的主要发现是,尽管该分析中包括复杂的患者和病变,但 OA 似乎是治疗钙化冠状动脉开口病变的一种可行且安全的治疗选择。